PURPOSE OF REVIEW: [^(177)Lu]Lu-PSMA-617 is a radiopharmaceutical that emits beta-minus radiation and targets prostate-specific membrane antigen (PSMA)-positive prostate cancer. Despite its clinical success, there are still patients not showing sufficient response rates. This review compiles latest studies aiming at therapy improvement in [^(177)Lu]Lu-PSMA-617-naïve and -resistant patients by alternative or combination …